



## Common Drug Review \*

### Submission Status

**Product:** Somavert  
**Generic Name:** pegvisomant  
**Manufacturer:** Pfizer Canada Inc.  
**Submission Type:** New  
**Date Submission Received:** 2006-Jan-25      **Date NOC Issued:** 2005-Oct-17  
**Targeted CEDAC Meeting:** 2006-May-17      **Priority Review Granted:** Denied

Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments	
1	Submission Deemed Complete	5	2006-Feb-01	2006-Feb-01	Priority review requested. Priority review denied February 1, 2006.
2	CDR Reviewers' Reports Completed • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer	45	2006-Apr-05	2006-Apr-07	Additional information requested February 10, 2006. Additional information received February 22, 2006. Additional information requested February 23, 2006. Revised information received March 7, 2006. Additional information received March 8, 2006. Additional information requested March 10, 2006. Revised information received March 16, 2006. Additional information received March 22, 2006. New due date for Reviewer's Reports to manufacturer is April 7, 2006.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7	2006-Apr-17	2006-Apr-19	New due date for Manufacturer's comments is April 19, 2006.
4	Reviewers' Reply to Manufacturer's Comments Completed	7	2006-Apr-26	2006-Apr-26	
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2006-May-03	2006-May-03	
6	CEDAC Meeting		2006-May-17	2006-May-17	
7	CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer	5	2006-May-25	2006-May-25	
8	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10	2006-Jun-08	2006-Jun-08	Request for reconsideration received June 8, 2006.
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5			
<b>OR</b>					
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
<b>OR</b>					
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates	2006-Jul-26	2006-Jul-26	
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5	2006-Aug-02	2006-Aug-02	

\* Refer to the Procedure for Common Drug Review on the Common Drug Review section of [www.cadth.ca](http://www.cadth.ca) for more details.

\*\* The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on [www.cadth.ca](http://www.cadth.ca).

\*\*\* The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.